Goldman Sachs Group Inc. Sells 4,782 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Goldman Sachs Group Inc. cut its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 13.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,257 shares of the company’s stock after selling 4,782 shares during the period. Goldman Sachs Group Inc. owned 0.06% of Immunocore worth $927,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IMCR. Baker BROS. Advisors LP boosted its position in Immunocore by 53.3% in the first quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company’s stock valued at $68,913,000 after buying an additional 807,338 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Immunocore by 5.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company’s stock valued at $209,228,000 after buying an additional 351,610 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in Immunocore by 176.9% in the first quarter. Frazier Life Sciences Management L.P. now owns 301,170 shares of the company’s stock valued at $8,936,000 after buying an additional 192,408 shares during the period. Jefferies Financial Group Inc. acquired a new position in Immunocore in the fourth quarter valued at approximately $4,868,000. Finally, Fiera Capital Corp lifted its holdings in Immunocore by 3.2% in the first quarter. Fiera Capital Corp now owns 805,150 shares of the company’s stock valued at $23,889,000 after buying an additional 25,186 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Immunocore

In related news, insider David M. Berman sold 22,532 shares of the firm’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on IMCR shares. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a “buy” rating and a $65.00 target price for the company. Jefferies Financial Group initiated coverage on shares of Immunocore in a research note on Monday, August 25th. They issued a “buy” rating and a $48.00 target price for the company. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Monday, June 2nd. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Immunocore currently has a consensus rating of “Hold” and a consensus price target of $56.89.

Immunocore Stock Performance

Shares of IMCR opened at $33.18 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $39.33. The firm has a fifty day simple moving average of $33.89 and a 200 day simple moving average of $31.95. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -82.94 and a beta of 0.77. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. The company had revenue of $130.65 million during the quarter, compared to the consensus estimate of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The company’s quarterly revenue was up 30.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.23) EPS. Research analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.